Pharmacokinetic Study and Optimal Formulation of New Anti-Parkinson Natural Compound Schisantherin A
Our recent studies showed that schisantherin A (StA) is a promising candidate for PD treatment, but the pharmacokinetic profile of StA is largely unknown. The effects of different formulations on the pharmacokinetics and bioavailability of StA were investigated by HPLC equipped with a vacuum degasse...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | Parkinson's Disease |
Online Access: | http://dx.doi.org/10.1155/2015/951361 |
id |
doaj-459ab3a265c54cf1841f73a2ed5d9f63 |
---|---|
record_format |
Article |
spelling |
doaj-459ab3a265c54cf1841f73a2ed5d9f632020-11-24T22:49:50ZengHindawi LimitedParkinson's Disease2090-80832042-00802015-01-01201510.1155/2015/951361951361Pharmacokinetic Study and Optimal Formulation of New Anti-Parkinson Natural Compound Schisantherin AFei Sa0Bao Jian Guo1Sai Li2Zai Jun Zhang3Hok Man Chan4Ying Zheng5Simon Ming Yuen Lee6State Key Laboratory of Quality Research of Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Taipa, MacauInstitute of New Drug Research, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine & New Drug Research, College of Pharmacy, Jinan University, Guangdong, ChinaInstitute of New Drug Research, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine & New Drug Research, College of Pharmacy, Jinan University, Guangdong, ChinaState Key Laboratory of Quality Research of Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Taipa, MacauState Key Laboratory of Quality Research of Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Taipa, MacauState Key Laboratory of Quality Research of Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Taipa, MacauState Key Laboratory of Quality Research of Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Taipa, MacauOur recent studies showed that schisantherin A (StA) is a promising candidate for PD treatment, but the pharmacokinetic profile of StA is largely unknown. The effects of different formulations on the pharmacokinetics and bioavailability of StA were investigated by HPLC equipped with a vacuum degasser, a quaternary pump, a manual sampler, and an ultraviolet detector. The absolute bioavailability of StA in nanoemulsion formulation was significantly increased from 4.3% to 47.3%. To the best of our knowledge, this is the first report of absolute bioavailability for StA in rats and successful increase of bioavailability of StA by nanoemulsion formulation. The pharmacokinetic profiles of StA could be significantly improved by a safe nanoemulsion formulation. This study provides a successful example of advanced delivery system for improving the bioavailability of potential central nervous system (CNS) drug candidate with poor solubility. This novel approach could be an effective alternative solution to overcome the shortcomings of conventional poor drug delivery of CNS drugs. The results of present study not only indicate that StA has potential to be developed as a promising oral therapeutic agent for the management of PD but also shed light on novel way to improve bioavailability of PD drugs.http://dx.doi.org/10.1155/2015/951361 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Fei Sa Bao Jian Guo Sai Li Zai Jun Zhang Hok Man Chan Ying Zheng Simon Ming Yuen Lee |
spellingShingle |
Fei Sa Bao Jian Guo Sai Li Zai Jun Zhang Hok Man Chan Ying Zheng Simon Ming Yuen Lee Pharmacokinetic Study and Optimal Formulation of New Anti-Parkinson Natural Compound Schisantherin A Parkinson's Disease |
author_facet |
Fei Sa Bao Jian Guo Sai Li Zai Jun Zhang Hok Man Chan Ying Zheng Simon Ming Yuen Lee |
author_sort |
Fei Sa |
title |
Pharmacokinetic Study and Optimal Formulation of New Anti-Parkinson Natural Compound Schisantherin A |
title_short |
Pharmacokinetic Study and Optimal Formulation of New Anti-Parkinson Natural Compound Schisantherin A |
title_full |
Pharmacokinetic Study and Optimal Formulation of New Anti-Parkinson Natural Compound Schisantherin A |
title_fullStr |
Pharmacokinetic Study and Optimal Formulation of New Anti-Parkinson Natural Compound Schisantherin A |
title_full_unstemmed |
Pharmacokinetic Study and Optimal Formulation of New Anti-Parkinson Natural Compound Schisantherin A |
title_sort |
pharmacokinetic study and optimal formulation of new anti-parkinson natural compound schisantherin a |
publisher |
Hindawi Limited |
series |
Parkinson's Disease |
issn |
2090-8083 2042-0080 |
publishDate |
2015-01-01 |
description |
Our recent studies showed that schisantherin A (StA) is a promising candidate for PD treatment, but the pharmacokinetic profile of StA is largely unknown. The effects of different formulations on the pharmacokinetics and bioavailability of StA were investigated by HPLC equipped with a vacuum degasser, a quaternary pump, a manual sampler, and an ultraviolet detector. The absolute bioavailability of StA in nanoemulsion formulation was significantly increased from 4.3% to 47.3%. To the best of our knowledge, this is the first report of absolute bioavailability for StA in rats and successful increase of bioavailability of StA by nanoemulsion formulation. The pharmacokinetic profiles of StA could be significantly improved by a safe nanoemulsion formulation. This study provides a successful example of advanced delivery system for improving the bioavailability of potential central nervous system (CNS) drug candidate with poor solubility. This novel approach could be an effective alternative solution to overcome the shortcomings of conventional poor drug delivery of CNS drugs. The results of present study not only indicate that StA has potential to be developed as a promising oral therapeutic agent for the management of PD but also shed light on novel way to improve bioavailability of PD drugs. |
url |
http://dx.doi.org/10.1155/2015/951361 |
work_keys_str_mv |
AT feisa pharmacokineticstudyandoptimalformulationofnewantiparkinsonnaturalcompoundschisantherina AT baojianguo pharmacokineticstudyandoptimalformulationofnewantiparkinsonnaturalcompoundschisantherina AT saili pharmacokineticstudyandoptimalformulationofnewantiparkinsonnaturalcompoundschisantherina AT zaijunzhang pharmacokineticstudyandoptimalformulationofnewantiparkinsonnaturalcompoundschisantherina AT hokmanchan pharmacokineticstudyandoptimalformulationofnewantiparkinsonnaturalcompoundschisantherina AT yingzheng pharmacokineticstudyandoptimalformulationofnewantiparkinsonnaturalcompoundschisantherina AT simonmingyuenlee pharmacokineticstudyandoptimalformulationofnewantiparkinsonnaturalcompoundschisantherina |
_version_ |
1725674866734006272 |